China Drug Administration Accepts Junshi's Application to Combine Toripalimab With RemeGen's Drug; Junshi Shares Down 1%, RemeGen Down 3%

MT Newswires Live

08/11

China's National Medical Products Administration accepted Shanghai Junshi Biosciences' (SHA:688180, HKG:1877) application to market the drug toripalimab in combination with another drug developed by RemeGen (HKG:9995, SHA:688331), according to a Hong Kong bourse filing on Saturday.

During Monday's midday trade, Shanghai Junshi's Hong Kong shares slipped over 1%, while Shanghai shares fell less than 1%. RemeGen's shares dropped less than 3%.

The supplemental new drug application seeks to market toripalimab, with the trade name Tuoyi, in combination of RemeGen's disitamab vedotin as a treatment of HER2-expressing locally advanced or metastatic urothelial carcinoma.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2558990639"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2558990639\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2558990639?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-11 13:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2558990639","market":"sg","top_or_hot":-1,"title":"China Drug Administration Accepts Junshi's Application to Combine Toripalimab With RemeGen's Drug; Junshi Shares Down 1%, RemeGen Down 3%","media":"MT Newswires Live","content":"<html><body><p> China's National Medical Products Administration accepted <a href=\"https://laohu8.com/S/SHJBF\">Shanghai Junshi Biosciences</a>' (SHA:688180, HKG:1877) application to market the drug toripalimab in combination with another drug developed by RemeGen (HKG:9995, SHA:688331), according to a Hong Kong bourse filing on Saturday.</p><p>During Monday's midday trade, Shanghai Junshi's Hong Kong shares slipped over 1%, while Shanghai shares fell less than 1%. RemeGen's shares dropped less than 3%.</p><p>The supplemental new drug application seeks to market toripalimab, with the trade name Tuoyi, in combination of RemeGen's disitamab vedotin as a treatment of HER2-expressing locally advanced or metastatic urothelial carcinoma.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China Drug Administration Accepts Junshi's Application to Combine Toripalimab With RemeGen's Drug; Junshi Shares Down 1%, RemeGen Down 3%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina Drug Administration Accepts Junshi's Application to Combine Toripalimab With RemeGen's Drug; Junshi Shares Down 1%, RemeGen Down 3%\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-08-11 13:32</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> China's National Medical Products Administration accepted <a href=\"https://laohu8.com/S/SHJBF\">Shanghai Junshi Biosciences</a>' (SHA:688180, HKG:1877) application to market the drug toripalimab in combination with another drug developed by RemeGen (HKG:9995, SHA:688331), according to a Hong Kong bourse filing on Saturday.</p><p>During Monday's midday trade, Shanghai Junshi's Hong Kong shares slipped over 1%, while Shanghai shares fell less than 1%. RemeGen's shares dropped less than 3%.</p><p>The supplemental new drug application seeks to market toripalimab, with the trade name Tuoyi, in combination of RemeGen's disitamab vedotin as a treatment of HER2-expressing locally advanced or metastatic urothelial carcinoma.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2558990639","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2558990639","pubTimestamp":1754890349,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"China's National Medical Products Administration accepted Shanghai Junshi Biosciences'  application to market the drug toripalimab in combination with another drug developed by RemeGen , according to a Hong Kong bourse filing on Saturday.During Monday's midday trade, Shanghai Junshi's Hong Kong shares slipped over 1%, while Shanghai shares fell less than 1%. RemeGen's shares dropped less than 3%.The supplemental new drug application seeks to market toripalimab, with the trade name Tuoyi, in combination of RemeGen's disitamab vedotin as a treatment of HER2-expressing locally advanced or metastatic urothelial carcinoma.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688180":"君实生物","688331":"荣昌生物","BK1161":"生物科技","BK1574":"生物医药B类股","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","BK1583":"高瓴概念","BK0239":"医药制造","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","01877":"君实生物","BK1515":"抗疫概念","09995":"荣昌生物","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD"},"translate_title":"中国药品监督管理局受理君实将特瑞普利单抗与瑞美健药物联用的申请；君实股价下跌1%，RemeGen下跌3%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688180":0.9,"688331":0.9,"01877":0.9,"09995":0.9},"content_text":"China's National Medical Products Administration accepted Shanghai Junshi Biosciences' (SHA:688180, HKG:1877) application to market the drug toripalimab in combination with another drug developed by RemeGen (HKG:9995, SHA:688331), according to a Hong Kong bourse filing on Saturday.During Monday's midday trade, Shanghai Junshi's Hong Kong shares slipped over 1%, while Shanghai shares fell less than 1%. RemeGen's shares dropped less than 3%.The supplemental new drug application seeks to market toripalimab, with the trade name Tuoyi, in combination of RemeGen's disitamab vedotin as a treatment of HER2-expressing locally advanced or metastatic urothelial carcinoma.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}